Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.
Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.
复制标题
DOI：
10.3390/ijms221910524
复制
发表时间：
2021-09-29
影响因子：
5.6
通讯作者：
Park J
中科院分区：
文献类型：
--
作者：
Banik N;Yang SB;Kang TB;Lim JH;Park J
在过去的几十年里，肝素作为一种安全的药物和生物分子被广泛研究。肝素衍生物，包括低分子量肝素（LMWH）和肝素五糖，是目前临床上使用的有效抗凝剂。它们还被研究为用于治疗疾病的各种治疗用途的功能性生物分子或生物材料。肝素具有与硫酸乙酰肝素相似的分子结构，由于其独特的高安全性和生物相容性，可作为一种引人注目的生物医学。特别是，它最近引起了人们的注意，用于药物输送系统，生物材料为基础的组织工程，纳米制剂，和新的药物开发系统，通过分子式。近年来开发了多种新的基于肝素的生物分子和缀合物，目前正在评估其在临床应用中的用途。本文综述了近年来肝素衍生物在治疗各种疾病药物开发领域的研究进展。
Heparin has been extensively studied as a safe medicine and biomolecule over the past few decades. Heparin derivatives, including low-molecular-weight heparins (LMWH) and heparin pentasaccharide, are effective anticoagulants currently used in clinical settings. They have also been studied as functional biomolecules or biomaterials for various therapeutic uses to treat diseases. Heparin, which has a similar molecular structure to heparan sulfate, can be used as a remarkable biomedicine due to its uniquely high safety and biocompatibility. In particular, it has recently drawn attention for use in drug-delivery systems, biomaterial-based tissue engineering, nanoformulations, and new drug-development systems through molecular formulas. A variety of new heparin-based biomolecules and conjugates have been developed in recent years and are currently being evaluated for use in clinical applications. This article reviews heparin derivatives recently studied in the field of drug development for the treatment of various diseases.